Panlong Pharmaceutical announced that the company previously reviewed and approved the share repurchase plan. It plans to use 10 million yuan to 20 million yuan of its own capital to repurchase shares through centralized bidding for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date of review and approval by the board of directors; later, due to semi-annual equity distribution, the upper limit of the repurchase price was adjusted from 35.92 yuan/share to 35.82 yuan/share. On October 21, 2026, the company repurchased 116,175 shares for the first time, accounting for 0.085% of the total share capital. The highest transaction price was 20.29 yuan/share, the lowest transaction price was 20.25 yuan/share, and the total transaction amount was 2.355 million yuan. The company will continue to promote repurchases in the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.